This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (VERIFY)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
ClinicalTrials.gov Identifier:
NCT01876784
First received: June 11, 2013
Last updated: January 23, 2017
Last verified: January 2017
June 11, 2013
January 23, 2017
September 2013
August 2015   (Final data collection date for primary outcome measure)
Progression-Free Survival (PFS) [ Time Frame: Randomization until disease progression or death, assessed every 12 weeks (up to 22 months) ]
The PFS was defined as the time (in months) from randomization until the date of first documented disease progression or death (from any cause), whichever came first. Disease progression as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) was defined as: at least a 20% increase and absolute increase of 5 mm in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Analysis was performed by Kaplan-Meier method.
Determination of the efficacy (as assessed by progression-free survival) of vandetanib when compared to placebo in the patient population [ Time Frame: Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow-up). ]
Once 155 progression events have occurred. RECIST measurements taken every 12 weeks from randomization. Time point(s) at which outcome measure is assessed.
Complete list of historical versions of study NCT01876784 on ClinicalTrials.gov Archive Site
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Duration of Response. [ Time Frame: Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow up). RECIST measurements taken every 12 weeks from randomization ]
    Once 155 progression events have occurred.
  • Demonstration of an Improvement in Time to Worsening of Pain in Patients Treated With Vandetanib When Compared to Placebo in the Patient Population. [ Time Frame: Patient assessments at baseline, week 4, 8, 12 and then every 12 weeks thereafter, assess up to 25.5 months ]
    Once 155 progression events have occurred.
  • Evaluation of the Safety and Tolerability of Vandetanib Treatment in the Patient Population by Assessment of Adverse Events, Vital Signs, Laboratory Parameters and Electrocardiography. [ Time Frame: Safety assessments at baseline, Weeks 1, 2, 4, 8, 12 and then every 12 weeks thereafter ]
    Once 155 progression events have occurred.
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Objective Response Rate. [ Time Frame: Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow up). RECIST measurements taken every 12 weeks from randomization ]
    Once 155 progression events have occurred.
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Change in Tumour Size [ Time Frame: Assessed tumour size at screening, Weeks 7, 8 and then every 12 weeks thereafter and at Discontinuation visit, estimated time frame at 25.5 months. ]
    Once 155 progression events have occurred.
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Overall Survival [ Time Frame: Estimated time frame at 20 months after initial 25.5 months. ]
    Once 155 progression events have occurred when 25% of randomized patients have died due to any cause.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of V/F. [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then every 12 weeks thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occurred or up to individual progression of patient.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of Cmax [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then every 12 weeks thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occurred or up to individual progression of patient.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of AUCss [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then every 12 weeks thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occurred or up to individual progression of patient.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of CL/F [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then every 12 weeks thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occurred or up to individual progression of patient.
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Duration of Response. [ Time Frame: Estimated time frame at 20 months after initial 25.5 months. ]
    Once 155 progression events have occurred. Analysis of overall survival to be repeated when 50% of randomised patients have died due to any cause.
  • Demonstration of an Improvement in Time to Worsening of Pain in Patients Treated With Vandetanib When Compared to Placebo in the Patient Population. [ Time Frame: Patient assessments at baseline, week 4, 8, 12 and then 12 weekly thereafter, assess up to 25.5 months ]
    Estimated time frame up to 155 progression events have occured.
  • Evaluation of the Safety and Tolerability of Vandetanib Treatment in the Patient Population by Assessment of Adverse Events, Vital Signs, Laboratory Parameters and Electrocardiography. [ Time Frame: Safety assessments at baseline, Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter, assess up to 25.5 months ]
    Once 155 progression events have occurred.
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Objective Response Rate. [ Time Frame: Estimated time frame at 20 months after initial 25.5 months. ]
    Once 155 progression events have occurred. Analysis of overall survival to be repeated when 50% of randomised patients have died due to any cause.
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Change in Tumour Size [ Time Frame: Assessed tumour size at screening, Weeks 7, 8 and then 12 weekly thereafter and at Discontinuation visit, estimated time frame at 25.5 months. ]
    Once 155 progression events have occurred. Analysis of overall survival to be repeated when 50% of randomised patients have died due to any cause.
  • Determination of the Efficacy of Vandetanib When Compared to Placebo in the Patient Population as Assessed by Efficacy Variables Including Overall Survival [ Time Frame: Estimated time frame at 20 months after initial 25.5 months. ]
    Once 155 progression events have occurred. Analysis of overall survival to be repeated when 50% of randomised patients have died due to any cause.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of V/F. [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occured or up to individual progression of patient.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of Cmax [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occured or up to individual progression of patient.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of AUCss [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occured or up to individual progression of patient.
  • Evaluation of the Pharmacokinetics of Vandetanib in the Patient Population by Assessment of CL/F [ Time Frame: Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation. ]
    Estimated time frame up to 155 progression events have occured or up to individual progression of patient.
Not Provided
Not Provided
 
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.

Primary Objective:

To determine the efficacy (as assessed by progression-free survival [PFS]) of vandetanib when compared to placebo in participants with differentiated thyroid cancer that is either locally advanced or metastatic who are refractory or unsuitable for radioiodine therapy.

Secondary Objectives:

  • To determine the efficacy of vandetanib when compared to placebo in this participant population as assessed by efficacy variables including duration of response (DOR), objective response rate (ORR), change in tumour size (TS) and overall survival (OS).
  • To evaluate the pharmacokinetics (PK) of vandetanib in this participant population and potentially investigate any influence of participant demography and pathophysiology on vandetanib PK.
  • To demonstrate an improvement in time to worsening of pain (TWP) in participants treated with vandetanib when compared to placebo in this participant population.
  • To evaluate the safety and tolerability of vandetanib treatment in this participant population.
Participants who were receiving vandetanib as randomized treatment will be allowed, upon re-consent, to continue on open-label vandetanib if in the opinion of the Investigator the participant is still receiving benefit. Placebo participants who experience disease progression within 60 days of unblinding may be offered the option of treatment with open-label vandetanib if, in the Investigator's opinion, such treatment may be of clinical benefit to the participant. Approximately 2 years; duration will vary depending on individual participant response.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Differentiated Thyroid Cancer
  • Drug: Vandetanib (SAR390530)

    Pharmaceutical form: tablet

    Route of administration: oral

    Other Name: CAPRELSA
  • Drug: Placebo

    Pharmaceutical form: tablet

    Route of administration: oral

  • Experimental: Vandetanib
    Vandetanib 300 mg tablet, orally once daily until disease progression or death.
    Intervention: Drug: Vandetanib (SAR390530)
  • Placebo Comparator: Placebo
    Placebo matched to vandetanib tablet, orally once daily until disease progression or death.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
238
December 2019
August 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of informed consent to participate in the study as well as provision of informed consent to provide a sample of a previously obtained archival tumour biopsy.
  • Female or male aged 18 years and older with previously confirmed histological diagnosis of locally advanced or metastatic differentiated (excluding minimally invasive follicular) thyroid cancer not amenable to surgical resection, external beam radiotherapy or local therapy.
  • Measurable disease defined as at least one lesion, not irradiated within 12 weeks of the date of randomisation, that can be accurately measured at baseline.
  • Participants must have experienced progression within 14 months and be RAI-refractory/resistant or unsuitable for RAI.
  • Thyroid-stimulating hormone (TSH) suppression below 0.5 mU/L is required.
  • World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
  • Negative pregnancy test (urine or serum) for female participants of childbearing potential.

Exclusion Criteria:

  • Inadequate organ function as defined by: (1) Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) greater than 2.5 x upper limit of normal (ULN), or greater than 5.0 x ULN if judged by the Investigator to be related to liver metastases. (2) Serum bilirubin greater than 1.5 x ULN. This criterion does not apply to participants with known Gilbert's Disease. (3) Creatinine clearance <50 mL/min (calculated by Cockcroft-Gault formula).
  • Risk of prolonged interval between Q and T (QT) on an electrocardiogram (ECG) corrected for heart rate (QTc) as defined by: (1) Current therapy with any medication known to be associated with Torsades de pointes or potent inducers of cytochrome CYP3A4. (2) History of QT prolongation. (3) Congenital long QT syndrome. (4) QT interval corrected for heart rate by the Bazett's method (QTcB) correction unmeasurable or greater than 480 ms on screening ECG.
  • Previous therapy with approved or investigational tyrosine kinase or anti- vascular endothelial growth factor (VEGF) receptor inhibitors or targeted therapies (e.g. multi-targeted kinase inhibitors such as sorafenib, AMG-706, sunitinib, pazopanib, lenvatinib).
  • RAI therapy within 12 weeks prior to first dose of study drug, and radiation therapy other than RAI, including external beam, if not completed prior to randomization.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Brazil,   China,   Czech Republic,   Denmark,   France,   Italy,   Japan,   Poland,   Russian Federation,   Spain,   Sweden,   United States
Belgium,   Germany,   Hungary,   Romania,   United Kingdom
 
NCT01876784
D4203C00011
2013-000422-58 ( EudraCT Number )
LPS14813 ( Other Identifier: Sanofi )
No
Not Provided
Not Provided
Not Provided
Sanofi ( Genzyme, a Sanofi Company )
Genzyme, a Sanofi Company
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP